GRAIL (GRAL) Stock Price, News & Analysis

Company Overview

GRAIL, Inc. (NASDAQ: GRAL) is a healthcare company focused on developing blood-based screening technologies for the early detection of cancer. Its principal product is Galleri, a multi-cancer early detection test designed to identify DNA patterns associated with multiple types of cancer from a single blood sample.

Galleri is intended for use alongside recommended cancer screenings and is available by prescription through qualified healthcare providers in the United States. The test is offered as a laboratory-developed test and has not been approved or cleared by the U.S. Food and Drug Administration. GRAIL continues to conduct clinical and real-world studies to evaluate the test’s performance and potential role in cancer screening.

GRAIL was founded in 2016 as a healthcare-focused company launched with support from Illumina and became an independent, publicly traded company in 2024. The company is headquartered in Menlo Park, California, and is led by Chief Executive Officer Bob Ragusa. Its commercial and research activities are primarily focused on the United States.

Key Stats

• Today's Range: $141.00 to $155.18
• 50-Day Range: $75.11 to $158.92
• 52-Week Range: $41.50 to $166.48
• Volume: 1.07 million shs
• Average Volume: 977,237 shs
• Market Capitalization: $6.41 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $119.80
• Consensus Rating: Hold

GRAIL Stock Analysis - MarketRank™

GRAIL scored higher than 19% of companies evaluated by MarketBeat, and ranked 830th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

GRAIL has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 5 buy ratings, 6 hold ratings, and 1 sell rating.

Downside Risk

GRAIL has a consensus price target of $119.80, representing about 16.5% downside from its current price of $143.43.

Amount of Analyst Coverage

GRAIL has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for GRAIL are expected to decrease in the coming year, from ($10.07) to ($10.80) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GRAIL is -14.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GRAIL is -14.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GRAIL has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.64% of the float of GRAIL has been sold short.

Short Interest Ratio / Days to Cover

GRAIL has a short interest ratio ("days to cover") of 8.01.

Change versus previous month

Short interest in GRAIL has recently increased by 2.06%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GRAIL does not currently pay a dividend.

Dividend Growth

GRAIL does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.94

News Sentiment

GRAIL has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for GRAIL this week, compared to 9 articles on an average week.

Search Interest

Only 6 people have searched for GRAL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

19 people have added GRAIL to their MarketBeat watchlist in the last 30 days. This is an increase of 375% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, GRAIL insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,832,805.00 in company stock.

Percentage Held by Insiders

1.83% of the stock of GRAIL is held by insiders.

Percentage Held by Institutions

GRAIL has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 11/01/2026
• Next Earnings (Estimated): 11/04/2026
• UBS Global Healthcare Conference: 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GRAL
• Previous Symbol: NASDAQ:GRAL
• CIK: 1699031
• Web: grail.com
• Phone: (833) 694-2553
• Fax: N/A
• Employees: 910
• Year Founded: 2016

Price Target and Rating

• Average Price Target for GRAIL: $119.80
• High Price Target: $180.00
• Low Price Target: $56.00
• Potential Upside/Downside: -16.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($9.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$408.35 million
• Net Margins: -236.95%
• Pretax Margin: -320.38%
• Return on Equity: -15.88%
• Return on Assets: -14.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.95
• Quick Ratio: 10.95

Sales & Book Value

• Annual Sales: $147.17 million
• Price / Sales: 43.53
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $66.13 per share
• Price / Book: 2.17

Miscellaneous

• Outstanding Shares: 44,670,000
• Free Float: 43,849,000
• Market Cap: $6.41 billion
• Optionable: Optionable
• Beta: 2.83